Affiliation:
1. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John’s University, Queens, NY 11439, USA
Abstract
The objective of this study was to construct amodiaquine-loaded, folic acid-conjugated polymeric nanoparticles (FA-AQ NPs) to treat cancer that could be scaled to commercial production. In this study, folic acid (FA) was conjugated with a PLGA polymer followed by the formulation of drug-loaded NPs. The results of the conjugation efficiency confirmed the conjugation of FA with PLGA. The developed folic acid-conjugated nanoparticles demonstrated uniform particle size distributions and had visible spherical shapes under transmission electron microscopy. The cellular uptake results suggested that FA modification could enhance the cellular internalization of nanoparticulate systems in non-small cell lung cancer, cervical, and breast cancer cell types. Furthermore, cytotoxicity studies showed the superior efficacy of FA-AQ NPs in different cancer cells such as MDAMB-231 and HeLA. FA-AQ NPs had better anti-tumor abilities demonstrated via 3D spheroid cell culture studies. Therefore, FA-AQ NPs could be a promising drug delivery system for cancer therapy.
Funder
College of Pharmacy and Health Sciences (CPHS), St. John’s University
Doctoral Fellowship offered by the College of Pharmacy and Health Sciences at St. John’s University
NIH Academic Research Enhancement Award
Reference59 articles.
1. Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016–2021;Benjamin;JAMA Netw. Open,2022
2. Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives;Zhong;Signal Transduct. Target. Ther.,2021
3. Small molecules, big impact: 20 years of targeted therapy in oncology;Bedard;Lancet,2020
4. (2023, March 03). Limitations of Current Chemotherapy Regimes and Rising Incidence of Cancer Driving Growth of Support Therapies. Available online: https://www.thepharmaletter.com/article/limitations-of-current-chemotherapy-regimes-and-rising-incidence-of-cancer-driving-growth-of-support-therapies.
5. Overcoming cancer therapeutic bottleneck by drug repurposing;Zhang;Signal Transduct. Target. Ther.,2020
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献